Preclinical studies of targeted α therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2

British Journal of Cancer

Volumn 88, Issue 6, 2003, Pages 944-950

  Allen, B J ^a,b,c   Tian, Z ^a,c   Rizvi, S M A ^a,b   Li, Y ^a   Ranson, M ^c  

^a St George Cancer Care Centre   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

particle emitter 213Bi; Breast cancer; MDA MB 231 cell line; Plasminogen activation inhibitor type 2; Targeted therapy

Indexed keywords

BISMUTH 213; PENTETIC ACID; PLASMINOGEN ACTIVATOR INHIBITOR 2; RADIOISOTOPE; UROKINASE;

ALPHA RADIATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; FEMALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ALPHA PARTICLES; ANIMALS; BISMUTH; BREAST NEOPLASMS; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL; PLASMINOGEN ACTIVATOR INHIBITOR 2; SERINE PROTEINASE INHIBITORS; TUMOR CELLS, CULTURED;

EID: 0037464295     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600838     Document Type: Article

References (38)

1. Adams GP, Shaller CC, Chappell LL, Wu C, Horak EM, Simmons HH, Litwin S, Marks JD, Weiner LM, Brechbiel MW (2000) Delivery of the α-emitting radioisotope bismuth-213 to solid tumours by a single-chain Fv and diabody molecules. Nucl Med Biol 27: 339-346
2. Allen BJ (1999a) Can α immunotherapy succeed where other systemic therapies have failed? Nucl Med Commun 20: 205-207
3. Allen BJ (1999b) Targeted α therapy: evidence for efficacy of α-immunoconjugates in the management of micrometastatic cancer. Australas Radiol 43: 480-486
4. Allen BJ, Rizvi SMA, Li Y, Tian Z, Ranson M (2001a) In vitro and preclinical targeted α therapy for melanoma, breast, prostate and colorectal cancers. Critical Rev Oncol/Haem 3: 139-146
5. Allen BJ, Rizvi SMA, Tian Z (2001b) Preclinical targeted α therapy for subcutaneous melanoma. Melanoma Res 11: 175-182
6. Andreasen PA, Kjoller L, Christensen L, Duffy MJ (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22
7. 90Y. Int J Radidt Onco Biol Phys 10: 341
8. 213Bi. Radiochimica Acta 79: 145-149
9. 213Bi for α-particle-mediated radioimmunotherapy. J Label Compds Radiopharm 40: 341
10. Gleave M, Hsieh JT, Gao C, von Eshenbach AC, Chung LKW (1991) Acceleration of human prostate cancer in vivo by factors produced by prostate and bione fibroblasts. Cancer Res 51: 3753-3761
11. Hang MTN, Ranson M, Saunders DN, Liang XM, Bunn CL, Baker MS (1998) Pharmacokinetics and biodistribution of recombinant human plasminogen activator inhibitor type 2 (PAI2) in control and tumour xenograft-bearing mice. Fibrinol Proteol 12: 145-154
12. Horak E, Hartmann F, Garmestani K, Wu C, Brechbiel M, Gansow OA, Landolfi NF, Waldmann TA (1997) Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumour using lead-212-DOTA-AE1. Nucl Med 38: 1944-1950
13. Jankun J (1992) Antitumour activity of the type 1 plasminogen activator inhibitor and cytotoxic conjugate in vitro. Cancer Res 52: 5829-5832
14. Jankun J (1994) Targeting of drugs to tumours: the use of the plasminogen activator inhibitor as a ligand. In Targeting of Drugs, Vol. 4, Gregoriadis G, McCormack B, Poste G (eds) New York: Plenum Press, pp. 67-79
15. Jurcic GJ, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, Ballangrud AM, Hamacher KA, Ma D, Humm JL, Brechbiel MW, Molinet R, Scheinberg DA (2002) Targeted α particle immunotherapy for myeloid leukaemia. Blood 100: 1233-1239
16. Kennel SJ, Foote LJ, Lankford PK, Terzaghi-Howe M, Patterson H, Barkenbus J, Popp DM, Boll R, Mirzadeh S, Stabin M, Roeske JC (1999a) Radiotoxicity of bismuth-213 bound to membranes of monolayer and spheroid cultures of tumour cells. Radiat Res 151: 244-256
17. 213Bi. Br J Cancer 80: 175-184
18. Kruithof EKO, Baker MS, Bunn CL (1995) Biochemistry, cellular and molecular biology and clinical aspects of plasminogen activator inhibitor type-2. Blood 86: 4007-4024
19. Larsen RH, Akabani G, Welsh P, Zalutski MR (1998) The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro. Radiation Res 149: 155-162
20. Li Y, Tian Z, Rizvi SMA, Bander NH, Allen BJ (2002a) In vitro and prelinical studies of targeted α therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen labeled J591 antibody against the prostate specific membrane antigen. Prostate Cancer Prostatic Dis 5: 36-46
21. 213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in xenograft animal model. Br J Cancer 86: 1197-1203
22. Macklis RM, Lin JY, Beresford B, Atcher RW, Hines JJ, Humm JL (1992) Cellular kinetics, dosimetry, and radiobiology of α-partide radioimmunotherapy: induction of apoptosis. Radiat Res 130: 220-226
23. Macklis RM, Beresford BA, Palayoor S, Sweeney S, Humm JL (1993) Cell cycle alterations, apoptosis, and response to low-dose-rate radioimmunotherapy in lymphoma cells. Int J Oncol 2: 711-715
24. McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, Larson SM, Scheinberg DA (1998) Radioimmunotherapy with α-emitting nuclides. Eur J Nucl Med 25: 1341-1351
25. 213Bi generator system for therapeutic clinical applications: construction and operation. Appl Rad Isot 50: 895-904
26. 213Bi-J591) for radio-immunotherapy of prostate cancer. Cancer Res 60: 6095-6100
27. Nikula TK, McDevitt MR, Finn RD, Wu C, Kozak RW, Garmestani K, Brechbiel MW, Curcio MJ, Pippin CG, Tiffany-Jones L, Geerlings Sr MW, Apostolidis C, Molinet R, Geerlings Jr MW, Gansow OA, Scheinberg DA (1999) α-Emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. J Nucl Med 40: 166-176
28. Pollanen J, Stephens R, Vaheri A (1991) Directed plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res 57: 273-328
29. Ranson M, Tian Z, Andronicos NM, Rizvi SMA, Allen BJ (2002) In vitro cytotoxicity study of human breast cancer cells using Bi-213 labeled plasminogen activator type 2. Breast Cancer Res Treat 71: 149-159
30. Raso V (1990) The magic bullet - nearing the century mark. Semin Cancer Biol 1: 227-243
31. Rizvi SM, Sarkar S, Goozee G, Allen BJ (2000) Radioimmunoconjugates for targeted α therapy of malignant melanoma. Melanoma Res 10: 281-290
32. Rizvi SMR, Allen BJ, Tian Z, Sarkar S (2001) In vitro and preclinical studies of targeted α therapy for colorectal cancer. Colorectal Disease 3: 345-353
33. Rizvi SMR, Henniker AJ, Goozee G, Allen BJ (2002) In vitro testing of the leukaemia monoclonal antibody WM-53 labeled with α and β emitting radioisotopes. Leukaemia Res 26: 37-43
34. Schmitt M, Janicke F, Moniwa N, Chucholowski N, Pache L, Graeff H (1992) Tumour-associated urokinase-type plasminogen activator: biological and clinical significance. Biol Chem Hoppe-Seyler 373: 611-622
35. Schmitt M, Wilhelm OG, Reuning U, Kruger A, Harbeck N, Lengyel E, Graeff H, Gansbacher B, Kessler H, Burgle M, Sturzebecher J, Sped S, Magdolen V (2000) The urokinase plasminogen activation system as a novel target for tumor therapy. Fibrinol Proteol 14: 114-132
36. Van Geel JNC, Fuger J, Koch L (1994) Verfahern zur erzeugung von actinium-225 und Bismuth-213. European Patent No. 0 443 479 B1
37. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T, Wallace J (1998) United Kingdom Coordinating Committee guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 77: 1-10
38. Yang JL, Steetoo D, Wang Y, Ranson M, Berney CR, Ham JM, Russell PJ, Crowe PJ (2000) Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic target. Int J Cancer 89: 431-439